Published in J Clin Microbiol on May 28, 2008
Genomic diversity among drug sensitive and multidrug resistant isolates of Mycobacterium tuberculosis with identical DNA fingerprints. PLoS One (2009) 2.20
Susceptibility of Mycobacterium bovis BCG vaccine strains to antituberculous antibiotics. Antimicrob Agents Chemother (2008) 1.29
Resistant mutants of Mycobacterium tuberculosis selected in vitro do not reflect the in vivo mechanism of isoniazid resistance. J Antimicrob Chemother (2009) 1.29
Rapid diagnosis of tuberculosis and multidrug resistance using a MGIT 960 system. Ann Lab Med (2012) 1.13
Role of the dihydrofolate reductase DfrA (Rv2763c) in trimethoprim-sulfamethoxazole (co-trimoxazole) resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother (2010) 0.88
Frequency and Distribution of Tuberculosis Resistance-Associated Mutations between Mumbai, Moldova, and Eastern Cape. Antimicrob Agents Chemother (2016) 0.80
Isoniazid MIC and KatG Gene Mutations among Mycobacterium tuberculosis Isolates in Northwest of Iran. Iran J Basic Med Sci (2011) 0.78
Resistance of Mycobacterium tuberculosis to antibiotics in Lao PDR: first multicentric study conducted in 3 hospitals. BMC Infect Dis (2013) 0.78
Genotypic Analysis of Genes Associated with Independent Resistance and Cross-Resistance to Isoniazid and Ethionamide in Mycobacterium tuberculosis Clinical Isolates. Antimicrob Agents Chemother (2015) 0.76
Minor Contribution of inhA-15 Mutations to the Rapid Detection of Isoniazid Resistance in Mycobacterium Tuberculosis Isolates. Iran J Med Sci (2016) 0.75
Reliability of Mycobacterial Growth Indicator Tube (MGIT) 960 for the detection of isoniazid resistance in a tuberculosis endemic setting. Indian J Med Res (2014) 0.75
Molecular genetic basis of antimicrobial agent resistance in Mycobacterium tuberculosis: 1998 update. Tuber Lung Dis (1998) 11.56
inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis. Science (1994) 11.22
Evaluation of the BACTEC radiometric method for recovery of mycobacteria and drug susceptibility testing of Mycobacterium tuberculosis from acid-fast smear-positive specimens. J Clin Microbiol (1983) 10.49
Genotypic assessment of isoniazid and rifampin resistance in Mycobacterium tuberculosis: a blind study at reference laboratory level. J Clin Microbiol (1997) 5.09
Epidemiology of antituberculosis drug resistance (the Global Project on Anti-tuberculosis Drug Resistance Surveillance): an updated analysis. Lancet (2006) 4.73
The new tuberculosis. N Engl J Med (1992) 4.37
Multidrug-resistant tuberculosis. Ann Intern Med (1992) 4.06
Multicenter laboratory validation of the BACTEC MGIT 960 technique for testing susceptibilities of Mycobacterium tuberculosis to classical second-line drugs and newer antimicrobials. J Clin Microbiol (2006) 3.22
Multicenter evaluation of fully automated BACTEC Mycobacteria Growth Indicator Tube 960 system for susceptibility testing of Mycobacterium tuberculosis. J Clin Microbiol (2002) 3.06
High prevalence of KatG Ser315Thr substitution among isoniazid-resistant Mycobacterium tuberculosis clinical isolates from northwestern Russia, 1996 to 2001. Antimicrob Agents Chemother (2002) 3.01
Evaluation of the fully automated BACTEC MGIT 960 system for testing susceptibility of Mycobacterium tuberculosis to pyrazinamide, streptomycin, isoniazid, rifampin, and ethambutol and comparison with the radiometric BACTEC 460TB method. J Clin Microbiol (2004) 2.76
Mutations at amino acid position 315 of the katG gene are associated with high-level resistance to isoniazid, other drug resistance, and successful transmission of Mycobacterium tuberculosis in the Netherlands. J Infect Dis (2000) 2.73
Studies on isoniazid and tubercle bacilli. II. The growth requirements, catalase activities, and pathogenic properties of isoniazid-resistant mutants. Am Rev Tuberc (1954) 2.62
Evaluation of automated BACTEC MGIT 960 system for testing susceptibility of Mycobacterium tuberculosis to four major antituberculous drugs: comparison with the radiometric BACTEC 460TB method and the agar plate method of proportion. J Clin Microbiol (2002) 2.62
Nosocomial transmission of multidrug-resistant tuberculosis among HIV-infected persons--Florida and New York, 1988-1991. MMWR Morb Mortal Wkly Rep (1991) 2.48
Simple and rapid identification of the Mycobacterium tuberculosis complex by immunochromatographic assay using anti-MPB64 monoclonal antibodies. J Clin Microbiol (1999) 2.14
Contribution of kasA analysis to detection of isoniazid-resistant Mycobacterium tuberculosis in Singapore. Antimicrob Agents Chemother (1999) 2.02
Overexpression of inhA, but not kasA, confers resistance to isoniazid and ethionamide in Mycobacterium smegmatis, M. bovis BCG and M. tuberculosis. Mol Microbiol (2002) 1.99
Differential identification of mycobacteria. I. Tests on catalase activity. Am Rev Respir Dis (1966) 1.89
Genomic mutations in the katG, inhA and aphC genes are useful for the prediction of isoniazid resistance in Mycobacterium tuberculosis isolates from Kwazulu Natal, South Africa. Tuber Lung Dis (2000) 1.83
Detection of mutations associated with isoniazid resistance in Mycobacterium tuberculosis isolates from China. J Clin Microbiol (2005) 1.78
New real-time PCR able to detect in a single tube multiple rifampin resistance mutations and high-level isoniazid resistance mutations in Mycobacterium tuberculosis. J Clin Microbiol (2002) 1.50
Molecular characterization of isoniazid-resistant Mycobacterium tuberculosis clinical isolates in Lithuania. Antimicrob Agents Chemother (2003) 1.44
Disequilibrium in distribution of resistance mutations among Mycobacterium tuberculosis Beijing and non-Beijing strains isolated from patients in Germany. Antimicrob Agents Chemother (2005) 1.43
Mutations in the rpoB and katG genes leading to drug resistance in Mycobacterium tuberculosis in Latvia. J Clin Microbiol (2002) 1.35
The susceptibility of Mycobacterium tuberculosis to isoniazid and the Arg-->Leu mutation at codon 463 of katG are not associated. J Clin Microbiol (2001) 1.27
Molecular analysis of rifampin and isoniazid resistance of Mycobacterium tuberculosis clinical isolates in Seville, Spain. Tuber Lung Dis (1999) 1.25
Evaluation of BACTEC MGIT 960 PZA medium for susceptibility testing of Mycobacterium tuberculosis to pyrazinamide (PZA): compared with the results of pyrazinamidase assay and Kyokuto PZA test. Diagn Microbiol Infect Dis (2002) 1.22
Molecular analysis of isoniazid resistance in Mycobacterium tuberculosis isolates recovered from South Korea. Diagn Microbiol Infect Dis (2003) 1.22
Molecular analysis of isoniazid and rifampin resistance in Mycobacterium tuberculosis isolates recovered from Barcelona. Microb Drug Resist (2005) 1.05
Exclusive mutations related to isoniazid and ethionamide resistance among Mycobacterium tuberculosis isolates from Korea. Int J Tuberc Lung Dis (2000) 0.98
Molecular characterization of isoniazid-resistant Mycobacterium tuberculosis clinical strains isolated in the Philippines. Int J Antimicrob Agents (2004) 0.93
Understanding the action of INH on a highly INH-resistant Mycobacterium tuberculosis strain using Genechips. Tuberculosis (Edinb) (2006) 0.92
Mutations responsible for Mycobacterium tuberculosis isoniazid resistance in Italy. Int J Tuberc Lung Dis (2005) 0.87
[Evaluation of the BACTEC MGIT 960 system for drug susceptibility testing of Mycobacterium tuberculosis isolates compared with the proportion method on solid media]. Kekkaku (2001) 0.85
[BACTEC MGIT 960 system for drug susceptibility testing of Mycobacterium tuberculosis: a study using external quality assessment strains]. Kekkaku (2006) 0.81
KatG sequence deletion is not the major cause of isoniazid resistance in Japanese and Yemeni Mycobacterium tuberculosis isolates. Mol Cell Probes (1995) 0.81
[Comparative study of bactec MGIT 960 AST and conventional proportion method using Ogawa medium for the drug susceptibility testing of Mycobacterium tuberculosis to isoniazid]. Kekkaku (2007) 0.77
Epidemiology of antituberculosis drug resistance 2002-07: an updated analysis of the Global Project on Anti-Tuberculosis Drug Resistance Surveillance. Lancet (2009) 7.22
Delamanid for multidrug-resistant pulmonary tuberculosis. N Engl J Med (2012) 6.73
Specific detection of tuberculosis infection: an interferon-gamma-based assay using new antigens. Am J Respir Crit Care Med (2004) 5.78
IMP-4 and OXA beta-lactamases in Acinetobacter baumannii from Singapore. J Antimicrob Chemother (2007) 1.98
Hypervariable loci that enhance the discriminatory ability of newly proposed 15-loci and 24-loci variable-number tandem repeat typing method on Mycobacterium tuberculosis strains predominated by the Beijing family. FEMS Microbiol Lett (2007) 1.83
Taking the chaos out of genetic patchiness: seascape genetics reveals ecological and oceanographic drivers of genetic patterns in three temperate reef species. Mol Ecol (2010) 1.80
Serodiagnosis of Mycobacterium avium-complex pulmonary disease using an enzyme immunoassay kit. Am J Respir Crit Care Med (2007) 1.75
Promising loci of variable numbers of tandem repeats for typing Beijing family Mycobacterium tuberculosis. J Med Microbiol (2008) 1.52
Proposal of a consensus set of hypervariable mycobacterial interspersed repetitive-unit-variable-number tandem-repeat loci for subtyping of Mycobacterium tuberculosis Beijing isolates. J Clin Microbiol (2013) 1.39
Population structure analysis of the Mycobacterium tuberculosis Beijing family indicates an association between certain sublineages and multidrug resistance. Antimicrob Agents Chemother (2008) 1.32
Protein tyrosine kinase Syk in mast cell signaling. Mol Immunol (2002) 1.28
Evaluation of personal dose equivalent using optically stimulated luminescent dosemeters in Marumori after the Fukushima nuclear accident. Radiat Prot Dosimetry (2012) 1.26
A steady increase in nontuberculous mycobacteriosis mortality and estimated prevalence in Japan. Ann Am Thorac Soc (2014) 1.25
IMP-1 and a novel metallo-beta-lactamase, VIM-6, in fluorescent pseudomonads isolated in Singapore. Antimicrob Agents Chemother (2004) 1.18
Assessment of chimeric mice with humanized liver as a tool for predicting circulating human metabolites. Drug Metab Pharmacokinet (2010) 1.16
Isolation by oceanographic distance explains genetic structure for Macrocystis pyrifera in the Santa Barbara Channel. Mol Ecol (2011) 1.16
Comparison of the sensitivity and specificity of two whole blood interferon-gamma assays for M. tuberculosis infection. J Infect (2008) 1.13
NAT2 genotype guided regimen reduces isoniazid-induced liver injury and early treatment failure in the 6-month four-drug standard treatment of tuberculosis: a randomized controlled trial for pharmacogenetics-based therapy. Eur J Clin Pharmacol (2012) 1.12
Automated identification systems and Burkholderia pseudomallei. J Clin Microbiol (2003) 1.10
[Leukopenia due to anti-tuberculous chemotherapy including rifampicin and isoniazid]. Kekkaku (2004) 1.07
A case of resistance beyond extensively drug-resistant tuberculosis in Japan. Eur Respir J (2013) 1.06
Clonal expansion of multidrug-resistant and extensively drug-resistant tuberculosis, Japan. Emerg Infect Dis (2010) 1.05
[Mycobacterium shinshuense isolated from cutaneous ulcer lesion of right lower extremity in a 37-year-old woman]. Kekkaku (2004) 1.04
Clinical factors on cavitary and nodular bronchiectatic types in pulmonary Mycobacterium avium complex disease. Intern Med (2008) 1.04
Rapid detection of Mycobacterium tuberculosis in respiratory samples by transcription-reverse transcription concerted reaction with an automated system. J Clin Microbiol (2005) 0.99
[Cross-resistance between rifampicin and rifabutin among multi-drug resistant Mycobacterium tuberculosis strains]. Kekkaku (2009) 0.98
Identifying critical regions in small-world marine metapopulations. Proc Natl Acad Sci U S A (2011) 0.98
Comparison of rifabutin susceptibility and rpoB mutations in multi-drug-resistant Mycobacterium tuberculosis strains by DNA sequencing and the line probe assay. J Infect Chemother (2010) 0.98
[Comparison of BBL Mycoprep and 2%NaOH decontamination procedures for MGIT]. Kekkaku (2008) 0.96
Computerized surveillance system of tuberculosis in Japan: its evolution, achievement and challenges. Kekkaku (2012) 0.94
[Clinical evaluation of acid-fast smear examination with light emitting diode fluorescent microscopy]. Kekkaku (2009) 0.94
Turbulent dispersal promotes species coexistence. Ecol Lett (2010) 0.94
Pharmacokinetics and 48-week efficacy of nevirapine: 400 mg versus 600 mg per day in HIV-tuberculosis coinfection receiving rifampicin. Antivir Ther (2008) 0.94
Diagnosis of active tuberculous serositis by antigen-specific interferon-gamma response of cavity fluid cells. Clin Infect Dis (2007) 0.93
Mycobacterium heckeshornense lung infection that was diagnosed as Mycobacterium xenopi disease by DNA-DNA hybridization (DDH). Intern Med (2011) 0.93
Radiation dose to patients and radiologists during transcatheter arterial embolization: comparison of a digital flat-panel system and conventional unit. AJR Am J Roentgenol (2005) 0.93
Clonal spread of IMP-1-producing Pseudomonas aeruginosa in two hospitals in Singapore. J Clin Microbiol (2004) 0.93
Successful treatment with faropenem and clarithromycin of pulmonary Mycobacterium abscessus infection. J Infect Chemother (2002) 0.93
Contact investigation in a primary school using a whole blood interferon-gamma assay. J Infect (2009) 0.92
[Agranulocytosis due to anti-tuberculosis drugs including isoniazid (INH) and rifampicin (RFP)--a report of four cases and review of the literature]. Kekkaku (2003) 0.92
Social course patterns of urban dwellers with tuberculosis under fragile living conditions in Tokyo, Japan. J Epidemiol (2006) 0.92
Changing seascapes, stochastic connectivity, and marine metapopulation dynamics. Am Nat (2012) 0.91
Epidemiology of Pulmonary Nontuberculous Mycobacterial Disease, Japan(1). Emerg Infect Dis (2016) 0.91
Absorption, metabolism and excretion of [(14)C]mirabegron (YM178), a potent and selective β(3)-adrenoceptor agonist, after oral administration to healthy male volunteers. Drug Metab Dispos (2012) 0.91
[Management of adverse effects with antituberculosis chemotherapy]. Kekkaku (2011) 0.90
Isothermal RNA sequence amplification method for rapid antituberculosis drug susceptibility testing of Mycobacterium tuberculosis. J Clin Microbiol (2005) 0.90
Comprehensive multicenter evaluation of a new line probe assay kit for identification of Mycobacterium species and detection of drug-resistant Mycobacterium tuberculosis. J Clin Microbiol (2012) 0.89
Tuberculosis infection among homeless persons and caregivers in a high-tuberculosis-prevalence area in Japan: a cross-sectional study. BMC Infect Dis (2011) 0.89
Synthesis of Arylsilanes via Palladium(0)-Catalyzed Silylation of Aryl Halides with Hydrosilane. J Org Chem (1997) 0.88
[Microbiologically identified isolates of Mycobacterium heckeshornense in two patients]. Kekkaku (2006) 0.87
[Tuberculosis control in Shinjuku Ward, Tokyo--promoting the DOTS program and its outcome]. Kekkaku (2008) 0.87
Genetic and phenotypic characterization of pyrazinamide-resistant mycobacterium tuberculosis complex isolates in Japan. Diagn Microbiol Infect Dis (2004) 0.86
Prooxidant activity of curcumin: copper-dependent formation of 8-hydroxy-2'-deoxyguanosine in DNA and induction of apoptotic cell death. Toxicol In Vitro (2004) 0.86
Evaluation of a line probe assay for the rapid detection of gyrA mutations associated with fluoroquinolone resistance in multidrug-resistant Mycobacterium tuberculosis. J Med Microbiol (2010) 0.86
[Thoracic malignancies in patients with chronic tuberculous empyema]. Kekkaku (2004) 0.86
[Drug resistance in recurrent cases of tuberculosis]. Kekkaku (2004) 0.85
Carbapenemase and efflux pump genes in Acinetobacter calcoaceticus Acinetobacter baumannii complex strains from Singapore. J Antimicrob Chemother (2007) 0.85
[Stability for long-term storage and reproducibility of positivity in the panel test slide prepared with the polyacrylamide-based artificial sputum]. Kekkaku (2008) 0.85
[Coexistence of lung cancer and active pulmonary mycobacteriosis]. Kekkaku (2005) 0.85
Effective dose during abdominal three-dimensional imaging with a flat-panel detector angiography system. Radiology (2009) 0.84
Heterogeneous vancomycin-resistant Staphylococcus aureus (hetero-VISA) in Singapore. Int J Antimicrob Agents (2005) 0.84
[Coexisting lung cancer and active pulmonary mycobacteriosis]. Nihon Kokyuki Gakkai Zasshi (2007) 0.84
Clinical evaluation of serodiagnosis of active tuberculosis by multiple-antigen ELISA using lipids from Mycobacterium bovis BCG Tokyo 172. Clin Chem Lab Med (2005) 0.84
[Rapid, simple genotyping method by the variable numbers of tandem repeats (VNTR) for Mycobacterium tuberculosis isolates in Japan--analytical procedure of JATA (12)-VNTR]. Kekkaku (2008) 0.84
Presence of a temperature gradient among genital tract portions and the thermal changes within these portions over the estrous cycle in beef cows. J Reprod Dev (2012) 0.84
An evaluation of the recovery of mycobacteria from urine specimens using the automated Mycobacteria Growth Indicator Tube system (BACTEC MGIT 960). J Med Microbiol (2008) 0.83
Prospective evaluation of simply modified MODS assay: an effective tool for TB diagnosis and detection of MDR-TB. Infect Drug Resist (2012) 0.83
Pulmonary Mycobacterium intermedium disease in an elderly man with healed pulmonary tuberculosis. J Clin Microbiol (2005) 0.83
O6-methylguanine-DNA methyltranspherase gene expression in gliomas by means of real-time quantitative RT-PCR and clinical response to nitrosoureas. Int J Cancer (2003) 0.83
[Clinical application of testing methods on acid-fast bacteria]. Kekkaku (2005) 0.83
CD24 expression is associated with progression of gastric cancer. Hepatogastroenterology (2012) 0.83
[Drug-induced hepatotoxicity caused by anti-tuberculosis drugs in tuberculosis patients complicated with chronic hepatitis]. Kekkaku (2008) 0.83
Mixed pulmonary infection with three types of nontuberculous mycobacteria. Intern Med (2013) 0.82
[Bone and joint tuberculosis concurrent with tuberculosis of other organs]. Kekkaku (2007) 0.82
[The current status and future issues on anti-tuberculosis campaign in Japan (5) The status and problems related to molecular epidemiological studies on tuberculosis organisms]. Nihon Koshu Eisei Zasshi (2009) 0.82
MUTYH-associated colorectal cancer and adenomatous polyposis. Surg Today (2013) 0.82
TOM1L1 is a Lyn substrate involved in FcepsilonRI signaling in mast cells. J Biol Chem (2007) 0.82
[Nontuberculous mycobacteriosis mortality in Japan]. Kekkaku (2011) 0.82
[BACTEC MGIT 960 system for drug susceptibility testing of Mycobacterium tuberculosis: a study using external quality assessment strains]. Kekkaku (2006) 0.81
MDR TB transmission, Singapore. Emerg Infect Dis (2013) 0.81
Non-acid-fastness in Mycobacterium tuberculosis ΔkasB mutant correlates with the cell envelope electron density. Tuberculosis (Edinb) (2012) 0.81
[Application of interlocking detachable coil (IDC) in superselective bronchial artery embolization]. Nihon Kokyuki Gakkai Zasshi (2004) 0.81
Management of adverse events in patients with metastatic renal cell carcinoma treated with sunitinib and clinical outcomes. Anticancer Res (2013) 0.81
Emerging problems with plasmid-mediated DHA and CMY AmpC beta-lactamases in Enterobacteriaceae in Singapore. Int J Antimicrob Agents (2007) 0.80
Comparative evaluation of three immunochromatographic identification tests for culture confirmation of Mycobacterium tuberculosis complex. BMC Infect Dis (2014) 0.80
Comparison of performance in two diagnostic methods for tuberculosis infection. Med Microbiol Immunol (2008) 0.80
Mycobacterium shinjukuense sp. nov., a slowly growing, non-chromogenic species isolated from human clinical specimens. Int J Syst Evol Microbiol (2010) 0.80
Poor nutritional status before and during chemotherapy leads to worse prognosis in unresectable advanced or recurrent colorectal cancer. Int Surg (2015) 0.80
Successful Treatment of Peritoneal Dialysis-related Peritonitis due to Mycobacterium iranicum. Intern Med (2016) 0.80